Breast Cancer Study Primary Endpoint Should Be Time To Progression - Cmte.
Executive Summary
Time to progression should replace response rate as the primary endpoint in clinical trials for first-line hormonal drugs that treat metastatic breast cancer, FDA's Oncologic Drugs Advisory Committee said Sept. 10.